You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 139 No. 8, August 2003 TABLE OF CONTENTS
  Archives
  •  Online Features
  Off-Center Fold
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Dermatology
 •Dermatologic Disorders
 •Diagnosis
 •Dermatologic Disorders, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Rash With Regional Lymphadenopathy—Diagnosis

Arch Dermatol. 2003;139:1075-1080.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Diagnosis: Localized cutaneous leishmaniasis.

MICROSCOPIC, RADIOLOGIC, AND LABORATORY FINDINGS AND CLINICAL COURSE

Histologic examination revealed a dense dermal infiltrate composed predominantly of histiocytes and lymphocytes with scattered plasma cells forming, in areas, an ill-defined granulomatous component. Within histiocytes, there were occasional intracytoplasmic 2- to 4-µm organisms consistent with Leishmania species (Figure 3). A computed tomographic scan revealed a left lower thoracic lymphatic cord and a 2.5-cm left inguinal lymph node. Culture on Novy-MacNeal-Nicolle medium from the Centers for Disease Control and Prevention confirmed the species as Leishmania viannia panamensis (formerly known as Leishmania braziliensis panamensis).


 
Figure appears in full text version.
Figure 3.


Our patient received 3 days of treatment with liposome-encapsulated amphotericin B before therapy with the pentavalent ammonial compound sodium stibogluconate (Pentostam) was initiated, with the intent to treat at a dosage of 1600 mg/d for 20 days. A response to treatment was evident by day 4 of the sodium stibogluconate therapy, with a decrease in the erythema and induration of the skin . . . [Full Text of this Article]

DISCUSSION



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Rash With Regional Lymphadenopathy—Quiz Case
Valentina R. Bradley, Vincent Liu, and Harley A. Haynes
Arch Dermatol. 2003;139(8):1075-1080.
EXTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.